ALCEDIAG

ALCEDIAG is a biotechnology startup dedicated to developing biomarker-based diagnostics for Mental Health. The company focuses on personalized medicine, specifically the development of biological signatures for diagnostic tools, with a primary emphasis on mental health. ALCEDIAG's biomarkers are based on the analysis of RNA editing, an epigenetic mechanism altering the nature and conformation of RNA. Notably, its blood biomarkers have been linked to conditions such as depression and suicidal tendencies, showcasing potential pivotal breakthroughs in mental health diagnostics. ALCEDIAG's flagship product, EDITDIAG, is a blood test designed to diagnose mental disorders, proving its efficacy through extensive clinical testing. Moreover, the company has developed a platform to discover new biomarkers based on RNA editing, collaborating with other entities and commercializing EDITOX, a predictive test to assess neuropsychiatric adverse side effects associated with drug treatments. Founded in 2013, ALCEDIAG operates in the industries of Biotechnology, Health Care, and Health and Wellness. As a subsidiary of ALCEN, an industrial group active in diverse domains, the startup demonstrates potential for growth and impact in the mental health diagnostics sector.